AbbVie scores crucial phase 3 wins with Humira follow-up SkyriziAbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms Share XAbbVie scores crucial phase 3 wins with Humira follow-up Skyrizihttps://pharmaphorum.com/news/abbvie-scores-crucial-phase-3-wins-with-humira-follow-up-skyrizi/
Sanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypsSanofi and Regeneron’s Dupixent has had the US market for the treatment of chronic rhinosinusitis with nasal polyps Share XSanofi/Regeneron on notice as FDA reviews GSK’s Nucala for nasal polypshttps://pharmaphorum.com/news/dupixent-on-notice-as-fda-reviews-gsks-nucala-for-nasal-polyps/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
Holistic immunology: Supporting patients at every stage of their journeyAs part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to Share XHolistic immunology: Supporting patients at every stage of their journeyhttps://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/
J&J pays $6.5bn for Momenta and its inflammatory disease hopefulJohnson & Johnson is to buy Momenta Pharmaceuticals for $6.5 billion, adding potential inflammatory diseases blockbuster nipocalimab to Share XJ&J pays $6.5bn for Momenta and its inflammatory disease hopefulhttps://pharmaphorum.com/news/jj-pays-6-5bn-for-momenta-and-its-inflammatory-disease-hopeful/
Analysts question Gilead’s commitment to arthritis drug after FDA setbackThe FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage Share XAnalysts question Gilead’s commitment to arthritis drug after FDA setbackhttps://pharmaphorum.com/news/gilead-could-become/
Roche takes on Alexion as FDA approves satralizumab in NMOSDThe FDA has approved Roche’s satralizumab for the rare autoimmune disorder Neuromyelitis Optica Spectrum Disorder (NMOSD), under the Share XRoche takes on Alexion as FDA approves satralizumab in NMOSDhttps://pharmaphorum.com/news/roche-takes-on-alexion-as-fda-approves-satralizumab-in-nmosd/
Sanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionSanofi is to buy Principia Biopharma for up to $3.68 billion, adding a potential multiple sclerosis drug to Share XSanofi adds BTK inhibitors to pipeline with $3.68bn Principia Biopharma acquisitionhttps://pharmaphorum.com/news/sanofi-adds-btk-inhibitors-to-pipeline-with-3-68bn-principia-biopharma-acquisition/
Kymera Therapeutics begins potential $2bn R&D deal with SanofiUS biotech Kymera Therapeutics has begun a strategic collaboration with Sanofi to develop and market several drugs tackling immune-inflammatory disease, which Share XKymera Therapeutics begins potential $2bn R&D deal with Sanofihttps://pharmaphorum.com/news/kymera-therapeutics-begins-potential-2bn-rd-deal-with-sanofi/
